Enhanced formation and survival of CD4+ CD25hi Foxp3+ T-cells in chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 50, Issue 5, 2009, Pages 788-801

  Jak, Margot ^a   Mous, Rogier ^a   Remmerswaal, Ester B M ^a   Spijker, René ^a   Jaspers, Annelieke ^a   Yagüe, Adriana ^a   Eldering, Eric ^a   Van Lier, René A W ^a   Van Oers, Marinus H J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Apoptosis; Chronic lymphocytic leukemia; Regulatory T cells

Indexed keywords

CD27 ANTIGEN; CD45 ANTIGEN; CD70 ANTIGEN; FAS ANTIBODY; FLUDARABINE; PROTEIN BCL 2; PROTEIN NOXA; ROSCOVITINE; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL EXPANSION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA CELL; LYMPH NODE CELL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOPOIESIS; MALE; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD27; ANTIGENS, CD70; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CASE-CONTROL STUDIES; CD40 LIGAND; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; T-LYMPHOCYTES, REGULATORY;

EID: 68449093742     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190902803677     Document Type: Article

References (44)

1. + T cells with a cytotoxic phenotype in patients with B-chronic lymphocytic leukaemia (B-CLL). Clin Exp Immunol 2001;126:29-36.
2. + T cell subsets in chronic lymphocytic leukemia. J Immunol 1997;158:1482-1489.
3. -T cells in B-cell chronic lymphocytic leukemia. Blood 2003;102:1057-1063.
4. + CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005;106:2018-2025.
5. + regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS ONE 2006;1:e129.
6. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-949.
7. + regulatory T cells in adult life. Blood 2006;107:2830-2838.
8. + T cells in the periphery. Nat Rev Immunol 2007;7:231-237.
9. + regulatory T cells are derived by rapid turnover of memory populations in vivo. J Clin Invest 2006;116: 2423-2433.
10. + regulatory T cells are highly susceptible to CD95 ligand - but not to TCR-mediated cell death. J Immunol 2005;175:32-36.
11. +) T cells: A highly differentiated and apoptosis-prone population. Eur J Immunol 2001;31:1122-1131.
12. Maslanka K, Piatek T, Gorski J, Yassai M, Gorski J. Molecular analysis of T cell repertoires. Spectratypes generated by multiplex polymerase chain reaction and evaluated by radioactivity or fluorescence. Hum Immunol 1995;44:28-34.
13. Kater AP, Evers LM, Remmerswaal EB, Jaspers A, Oosterwijk MF, van Lier RA, et al. CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the antiapoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack. Br J Haematol 2004;127:404-415.
14. + T cells. J Immunol 2006;177:2775-2783.
15. Hintzen RQ, Lens SM, Beckmann MP, Goodwin RG, Lynch D, van Lier RA. Characterization of the human CD27-ligand, a novel member of the TNF gene family. J Immunol 1994;152:1762-1773.
16. Eldering E, Spek CA, Aberson HL, Grummels A, Derks IA, de Vos AF, et al. Expression profiling via novel multiplex assay allows rapid assessment of gene regulation in defined signalling pathways. Nucleic Acids Res 2003;31:e153.
17. Mackus WJ, Kater AP, Grummels A, Evers LM, Hooijbrink B, Kramer MH, et al. Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation. Leukemia 2005;19:427-434.
18. + T-cell clones during primary human cytomegalovirus infection. Blood 2006;108:3121-3127.
19. + T reg cells. J Exp Med 2006;203:1701-1711.
20. Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, et al. Expression of interleukin (IL)- 2 and IL-7-receptors discriminates between human regulatory and activated T cells. J Exp Med 2006;203:1693-1700.
21. + CD25 T cells. Blood 2007;110:2537-2544.
22. Smit LA, Hallaert DY, Spijker R, de GB, Jaspers A, Kater AP, et al. Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. Blood 2007;109:1660-1668.
23. Ranheim EA, Cantwell MJ, Kipps TJ. Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B cells. Blood 1995;85:3556-3565.
24. Hallaert DY, Spijker R, Jak M, Derks IA, Alves NL, Wensveen FM, et al. Crosstalk among Bcl-2 family members in B-CLL: Seliciclib acts via the Mcl-1/Noxa axis and gradual exhaustion of Bcl-2 protection. Cell Death Differ 2007;14: 1958-1967.
25. Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU, et al. IAP antagonists target cIAP1 to induce TNFa-dependent apoptosis. Cell 2007;131:682-693.
26. Wang L, Du F, Wang X. TNF-a induces two distinct caspase- 8 activation pathways. Cell 2008;133:693-703.
27. Miyawaki T, Uehara T, Nibu R, Tsuji T, Yachie A, Yonehara S, et al. Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood. J Immunol 1992;149:3753-3758.
28. + regulatory T-cell population by non-Hodgkin lymphoma. Blood 2008;111:5359-5370.
29. Schmid C, Isaacson PG. Proliferation centres in B-cell malignant lymphoma, lymphocytic (B-CLL): An immunophenotypic study. Histopathology 1994;24:445-451.
30. Kitada S, Zapata JM, Andreeff M, Reed JC. Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br J Haematol 1999;106:995-1004.
31. + T cells by producing CCL22. Eur J Immunol 2002;32:1403-1413.
32. Arens R, Baars PA, Jak M, Tesselaar K, van der Valk M, Van Oers MH, et al. Cutting edge: CD95 maintains effector T cell homeostasis in chronic immune activation. J Immunol 2005;174:5915-5920.
33. +. J Clin Invest 2003;112:1437-1443.
34. +Tcells. Eur J Immunol 2007;37:129-138.
35. McKenzie MD, Carrington EM, Kaufmann T, Strasser A, Huang DC, Kay TW, et al. Proapoptotic BH3-only protein Bid is essential for death receptor-induced apoptosis of pancreatic beta-cells. Diabetes 2008;57:1284-1292.
36. + regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 2006;24:1169-1177.
37. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002; 169:2756-2761.
38. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003;9: 606-612.
39. + CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 2006;177:7398-7405.
40. Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 2006;116:1935-1945.
41. Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 2008;105:3005-3010.
42. Hahntow IN, Schneller F, Oelsner M, Weick K, Ringshausen I, Fend F, et al. Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells. Leukemia 2004;18:747-755.
43. Schlagbauer-Wadl H, Klosner G, Heere-Ress E, Waltering S, Moll I, Wolff K, et al. Bcl-2 antisense oligonucleotides (G3139) inhibit Merkel cell carcinoma growth in SCID mice. J Invest Dermatol 2000;114:725-730.
44. O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki A, Koziner B, et al. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 2007;25: 1114-1120.